Literature DB >> 20698790

Longitudinal analysis of serological responses of adults to Helicobacter pylori antigens.

Guillermo I Perez-Perez1, Anna M Maw, Lani Feingold-Link, Jennifer Gunn, Andrea L Bowers, Cecilia Minano, Hilpi Rautelin, Timo U Kosunen, Martin J Blaser.   

Abstract

Because Helicobacter pylori persist for decades in the human stomach, the aim of this study was to examine the long-term course of H. pylori-specific serum immunoglobulin G (IgG) responses with respect to subclass and antigenic target. We studied paired serum samples obtained in 1973 and in 1994 in Vammala, Finland, from 64 healthy H. pylori-positive adults and from other healthy control subjects. H. pylori serum immunoglobulin A, IgG, and IgG subclass responses were determined by antigen-specific enzyme-linked immunosorbent assays. H. pylori-specific IgG1 and IgG4 subtype responses from 47 subjects were similar in 1973 and 1994, but not when compared with unrelated persons. H. pylori-specific IgG1:IgG4 ratios among the participants varied >1000-fold; however, 57 (89.1%) of 64 subjects had an IgG1:IgG4 ratio >1.0, consistent with a predominant IgG1 (Th1) response. Furthermore, ratios in individual hosts were stable over the 21-year period (r = 0.56; P < .001). The immune response to heat shock protein HspA was unchanged in 49 (77%) of the 64 subjects tested; of the 15 whose serostatus changed, all seroconverted and were significantly younger than those whose status did not change. These findings indicate that H. pylori-specific antibody responses are host-specific with IgG1:IgG4 ratios stable over 21 years, IgG1 responses predominating, and HspA seroconversion with aging.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20698790      PMCID: PMC2924458          DOI: 10.1086/655660

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  49 in total

Review 1.  Control of gastric acid secretion in health and disease.

Authors:  Mitchell L Schubert; David A Peura
Journal:  Gastroenterology       Date:  2008-05-12       Impact factor: 22.682

Review 2.  IgG4 breaking the rules.

Authors:  Rob C Aalberse; Janine Schuurman
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

3.  Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter-induced gastric atrophy.

Authors:  J G Fox; P Beck; C A Dangler; M T Whary; T C Wang; H N Shi; C Nagler-Anderson
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

4.  Host adaptation and immune modulation are mediated by homologous recombination in Helicobacter pylori.

Authors:  Karen Robinson; Michael F Loughlin; Rebecca Potter; Peter J Jenks
Journal:  J Infect Dis       Date:  2005-01-14       Impact factor: 5.226

5.  Decreasing prevalence of helicobacter antibodies in Finland, with reference to the decreasing incidence of gastric cancer.

Authors:  L Rehnberg-Laiho; H Rautelin; P Koskela; S Sarna; E Pukkala; A Aromaa; P Knekt; T U Kosunen
Journal:  Epidemiol Infect       Date:  2001-02       Impact factor: 2.451

6.  IgA antibodies in persisting Helicobacter pylori infection in Finnish adults.

Authors:  A Salomaa-Räsänen; T U Kosunen; J Karjalainen; A Aromaa; P Knekt; S Sarna; H Rautelin
Journal:  Clin Microbiol Infect       Date:  2006-03       Impact factor: 8.067

Review 7.  Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts.

Authors: 
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

8.  Evidence that cagA(+) Helicobacter pylori strains are disappearing more rapidly than cagA(-) strains.

Authors:  G I Perez-Perez; A Salomaa; T U Kosunen; B Daverman; H Rautelin; A Aromaa; P Knekt; M J Blaser
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

Review 9.  Role of type IV secretion in Helicobacter pylori pathogenesis.

Authors:  Steffen Backert; Matthias Selbach
Journal:  Cell Microbiol       Date:  2008-04-08       Impact factor: 3.715

Review 10.  Coadaptation of Helicobacter pylori and humans: ancient history, modern implications.

Authors:  John C Atherton; Martin J Blaser
Journal:  J Clin Invest       Date:  2009-09       Impact factor: 14.808

View more
  6 in total

1.  Helicobacter pylori and the birth cohort effect: evidence for stabilized colonization rates in childhood.

Authors:  Caroline M den Hoed; Anne J Vila; Ingrid L Holster; Guillermo I Perez-Perez; Martin J Blaser; Johan C de Jongste; Ernest J Kuipers
Journal:  Helicobacter       Date:  2011-10       Impact factor: 5.753

2.  Association between Helicobacter pylori and mortality in the NHANES III study.

Authors:  Yu Chen; Stephanie Segers; Martin J Blaser
Journal:  Gut       Date:  2013-01-08       Impact factor: 23.059

3.  The role of Th cell subsets in the control of Helicobacter infections and in T cell-driven gastric immunopathology.

Authors:  Iris Hitzler; Esther Kohler; Daniela B Engler; Ayca S Yazgan; Anne Müller
Journal:  Front Immunol       Date:  2012-06-01       Impact factor: 7.561

4.  A Case Control Study of the Seroprevalence of Helicobacter pylori Proteins and Their Association with Pancreatic Cancer Risk.

Authors:  Jennifer B Permuth; Shams Rahman; Dung-Tsa Chen; Tim Waterboer; Anna R Giuliano
Journal:  J Pancreat Cancer       Date:  2021-09-16

5.  Evaluating the relationship between serum immunoglobulin G (IgG) and A (IgA) anti-CagA antibody and the cagA gene in patients with dyspepsia.

Authors:  Hashem Fakhre-Yaseri; Ali Baradaran-Moghaddam; Mehdi Shekaraby; Hamid Reza Baradaran; Seyed Kamran Soltani-Arabshahi
Journal:  Iran J Microbiol       Date:  2017-04

6.  Antibody responses to a suite of novel serological markers for malaria surveillance demonstrate strong correlation with clinical and parasitological infection across seasons and transmission settings in The Gambia.

Authors:  Lindsey Wu; Julia Mwesigwa; Muna Affara; Mamadou Bah; Simon Correa; Tom Hall; Susheel K Singh; James G Beeson; Kevin K A Tetteh; Immo Kleinschmidt; Umberto D'Alessandro; Chris Drakeley
Journal:  BMC Med       Date:  2020-09-25       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.